Open Letter to ManagementDear Management,
The closing price for 2021 was 0.175 compared to 0.325 in 2020 (and 0.440 in 2019). Do you consider this a severe problem or not?!
- street cred has been gained with the R+F deal
- cash flow (should have been much better if you had brought Linda Pullan to the R+F table)
- ongoing negotiations for a global TFC 1067 deal
- ongoing in-vitro for antiviral to jump on the COVID-19 commercial train
- anti-aging is approaching clinical trial - that will compete with Botox
There's so many commercial opportunities, but the share price reflect that the investor community doesn't expect any substantial value to be added. I think this is a severe problem - do you agree or not?
It's not so much about finally close the TFC 1067-deal, but rather that trust has been eroded along the way. The expectations among investors are next to none. The low activity on this bullboard also reflect the interest in the company.
If you actually care about maximizing shareholder value, please use part of the payment to appoint another CEO - like it or not - that would probably double the share price overnight.